Alnylam's drug reduces bad cholesterol in early study
(Reuters) - Alnylam Pharmaceuticals Inc said an early-stage trial of its experimental cholesterol treatment showed the therapy reduced up to half the level of bad cholesterol in patients. The main goal of the study was to test the safety and tolerability of a single dose of the treatment, ALN-PCS -- which works by targeting a specific gene that is associated with high levels of bad cholesterol ...
Read more...
Heart risks 'not as suggested'
Doctors may be giving middle-aged men and women a false sense of security about their chances of suffering a heart attack or stroke, research suggests.
Read more...
ALN-PCS, Experimental Treatment, Successfully Lowers Bad Cholesterol: Study
(Reuters) - Alnylam Pharmaceuticals Inc said an early-stage trial of its experimental cholesterol treatment showed the therapy reduced up to half the level of bad cholesterol in patients.
Read more...
US FDA approves Pfizer's Inlyta for kidney cancer
WASHINGTON (Reuters) - Pfizer's Inlyta drug for patients with advanced kidney cancer got the nod from U.S. regulators on Friday, boosting the company's plans to offset plunging Lipitor sales. The Food and Drug Administration said the drug, known generically as axitinib, was effective at treating patients who did not respond to another drug for kidney cancer. Advanced kidney cancer starts in the ...
Read more...
Swimmers go with the flow of exercise
Swimming the ultimate exercise for Merritt Island family..
Read more...
|